Autoimmune diseases can affect just about every part of the body – and tens of millions of people. While most common in women ...
Thierry André and colleagues recently reported that nivolumab–ipilimumab provided an impressive absolute progression-free survival benefit at 36 months, which was 17% compared with nivolumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback